Abstract
The recent expansion of Indian biotechnology industry backed by strong R&D allocations sets the upward movement of the industry on a new growth trajectory intertwined with innovation and entrepreneurship. This is most likely to take off Indian biopharma industry from 'bio-generics' and 'bio-similars' to a higher pedestal where it may develop 'proprietary processes', carving a new niche for the growth of the sector, giving further push to R&D-intensive activities. The issue is how National Innovation System (NIS), which could provide initial manpower and financial support to the sector, responds to the growing specialisation of the Indian biopharma and help evolve new strategies to sustain the growth in the high-end biopharma sector.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Technology and Globalisation
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
